

Fw: Nicoventures: Pre-Submission meeting on a novel Nicotine Therapeutic Good [SEC=UNCLASSIFIED]

Peter Bird to. Mayada Kayali, Kerri Mackay

26/11/2013 06:23 PM

FYI - we are organising a meeting and I will explain further.

Thanks, Pete

Dr Peter Bird Head of Office Office of Medicines Authorisation Therapeutic Goods Administration

Tel: (02) 62328100

---- Forwarded by Peter Bird/TGA/Health on 26/11/2013 06:22 PM -----

From

To:

Peter.Bird

Cc: Date: Kylie.Lisson

26/11/2013 05:06 AM

Subject:

Re: Fw: Nicoventures: Pre-Submission meeting on a novel Nicotine Therapeutic Good

[SEC=UNCLASSIFIED]

Peter,

for date and time December 18th at 10am would be ideal, but if easier for you and others can do 19th or 20th, and be flexible with start time. We can be available for as long as you need during the day, however, if you can spare 90min for the session that would be great.

I will provide you with a formal agenda etc by the end of the week if that's ok.

Overall the intention is to provide you background, and seek feedback, on the products that we will be bringing for review and launch in Australia during 2014. Key areas we would like to cover:-

COMPANY - Nicoventures - who we are and what is our approach to new NRT products PRODUCTS - Review of the different technologies and data that support our products PROCESS - Regulatory update on UK submissions and anticipated regulatory route to market in Australia for Nicoventures and other Nicotine containing products

Q&A

Thanks again for making time to see us, this is an area of much focus globally and we are committed to bringing these products to market and so reducing the harm caused by smoking in the population.

Regards



Background on Nicoventures

Nicoventures is a consumer healthcare company established to focus exclusively on bringing nicotine products to smokers that can be licensed to medicines standards. It is a stand-alone company within the British American Tobacco Group, managed separately from the tobacco businesses. The Nicoventures team has extensive pharmaceutical experience of nicotine replacement therapy (NRT) coupled with an understanding of smoking behaviour, which we believe will be of immeasurable value in providing consumers with products that they want to use and that are substantially safer alternatives in comparison with their usual cigarettes.

The goal of reducing the harm caused by smoking is a public health benefit to which we openly aspire.

From: Peter.Bird

To:

Cc: Kylie.Lisson

Date: 24/11/2013 22:28

Subject: Fw: Nicoventures: Pre-Submission meeting on a novel Nicotine Therapeutic Good [SEC=UNCLASSIFIED]

Dear

I left a message on your mobile phone, but it has occurred to me that you are probably travelling and may not have picked it up. There should not be any problem with meeting that week and you may like to clarify an agenda and suggest a time and date. Kylie Lisson will organise my availability and that of others from the TGA that may need to attend.

Kind regards,

Peter

Dr Peter Bird Head of Office Office of Medicines Authorisation Therapeutic Goods Administration

Tel: (02) 62328100

---- Forwarded by Peter Bird/TGA/Health on 25/11/2013 09:24 AM ----

 From:
 Peter Bird/TGA/Health

 To:
 Peter Bird

 Date:
 20/11/2013 10:02 AM

Subject: Fw: Nicoventures: Pre-Submission meeting on a novel Nicotine Therapeutic Good [SEC=UNCLASSIFIED]

Sent by: Kylie Lisson

From: Nicoventures

To: Peter Bird <peter.bird

Date: 11/11/2013 10:52 AM

Subject: Nicoventures: Pre-Submission meeting on a novel Nicotine Therapeutic Good

Dear Peter.

in Australia to bring to market novel nicotine technologies. As such we would like to arrange an initial face-to-face meeting with TGA. Nicoventures representatives would be myself and our The purpose of the meeting would be to discuss our experiences in the US and UK plus our proposed first product and regulatory submission options in the Australia. We anticipate formal regulatory approval from MHRA for our first technology in the very near future, we hope to progress Australian submissions soon after this. will be in Australia from the UK the week of 16th December on other business, so it would be great if we could arrange an initial meeting to coincide with this. would be of particular benefit as he has lead similar dialogues recently with both the MHRA in the UK, and FDA in USA. Given the dynamic, and evolving, nature of this area we have found these face-to-face meetings to be extremely productive for us to better understand agency needs, and also to fully explain our medicines based approach to those agencies. Appreciate your time is at a premium, however, I hope you can find time during the week of 16th December to see us. Look forward to your response on this. Regards Nicoventures Limited

As discussed last week, Nicoventures Limited is in the process of initiating regulatory activity

Background on Nicoventures

www.nicoventures.co.uk

Nicoventures is a consumer healthcare company established to focus exclusively on bringing nicotine products to smokers that can be licensed to medicines standards. It is a stand-alone company within the British American Tobacco Group, managed separately from the tobacco businesses. The Nicoventures team has extensive pharmaceutical experience of nicotine replacement therapy (NRT) coupled with an understanding of smoking behaviour, which we believe will be of immeasurable value in providing consumers with products that they want to use and that are substantially safer alternatives in comparison with their usual cigarettes. The goal of reducing the harm caused by smoking is a public health benefit to which we openly aspire.

Nicoventures Limited

www.nicoventures.co.uk

Confidentiality Notice: The information in this document and attachments is confidential and may also be legally privileged. It is intended only for the use of the named recipient. Internet communications are not secure and therefore Nicoventures does not accept legal responsibility for the contents of this message.

If you are not the intended recipient, please notify us immediately and then delete this document. Do not disclose the contents of this document to any other person, nor take any copies.

Violation of this notice may be unlawful.

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information and has been sent in accordance with the TGA security policy.

If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author Immediately and delete all copies of this transmission."

Confidentiality Notice: The information in this document and attachments is confidential and may also be legally privileged. It is intended only for the use of the named recipient. Internet communications are not secure and therefore Nicoventures does not accept legal responsibility for the contents of this message.

If you are not the intended recipient, please notify us immediately and then delete this document. Do not disclose the contents of this document to any other person, nor take any copies.

Violation of this notice may be unlawful.